#ESMO20: Autolus provides glimpse of next-generation CAR-T program, showing early positive safety data

Max Gelman

Senior Editor

CAR-T therapies were hailed as a breakthrough when Novartis received the first FDA approval for Kymriah back in 2017. Though highly effective at treating …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ESMO20: Autolus provides glimpse of next-generation CAR-T program, showing early positive safety data

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Pfizer, GSK add risk of Guillain-Barré to RSV vaccine labels at FDA's request

#ES­MO20: Au­to­lus pro­vides glimpse of next-gen­er­a­tion CAR-T pro­gram, show­ing ear­ly pos­i­tive safe­ty da­ta

Senior Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

#ESMO20: Autolus provides glimpse of next-generation CAR-T program, showing early positive safety data